- Home
- SNTI vs CTM Comparison
SNTI vs CTM Comparison
Compare SNTI & CTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- CTM
- Stock Information
- Founded
- SNTI 2016
- CTM 2019
- Country
- SNTI United States
- CTM United States
- Employees
- SNTI N/A
- CTM N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- CTM EDP Services
- Sector
- SNTI Health Care
- CTM Technology
- Exchange
- SNTI Nasdaq
- CTM Nasdaq
- Market Cap
- SNTI 10.4M
- CTM 9.4M
- IPO Year
- SNTI N/A
- CTM N/A
- Fundamental
- Price
- SNTI $4.41
- CTM $0.32
- Analyst Decision
- SNTI Strong Buy
- CTM
- Analyst Count
- SNTI 1
- CTM 0
- Target Price
- SNTI $12.00
- CTM N/A
- AVG Volume (30 Days)
- SNTI 7.0M
- CTM 2.4M
- Earning Date
- SNTI 11-14-2024
- CTM 11-13-2024
- Dividend Yield
- SNTI N/A
- CTM N/A
- EPS Growth
- SNTI N/A
- CTM N/A
- EPS
- SNTI N/A
- CTM N/A
- Revenue
- SNTI N/A
- CTM $45,555,964.00
- Revenue This Year
- SNTI $254.47
- CTM $29.25
- Revenue Next Year
- SNTI $169.66
- CTM N/A
- P/E Ratio
- SNTI N/A
- CTM N/A
- Revenue Growth
- SNTI N/A
- CTM 3.12
- 52 Week Low
- SNTI $1.52
- CTM $0.12
- 52 Week High
- SNTI $16.94
- CTM $0.44
- Technical
- Relative Strength Index (RSI)
- SNTI 52.77
- CTM 60.55
- Support Level
- SNTI $4.62
- CTM $0.26
- Resistance Level
- SNTI $5.96
- CTM $0.38
- Average True Range (ATR)
- SNTI 1.63
- CTM 0.06
- MACD
- SNTI -0.14
- CTM 0.00
- Stochastic Oscillator
- SNTI 18.48
- CTM 43.83
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About CTM Castellum Inc.
Castellum Inc is engaged in providing information technology services. The company provides financial services, healthcare, and other users of large data applications with services that include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and MBSE. In addition to constantly innovating and enhancing organic capabilities, Castellum is acquiring technology companies in the areas of cybersecurity, information technology, electronic warfare, information warfare, and information operations with businesses in the defense, federal, civilian, and commercial markets.